Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2007 Oct;30(5):768-82.
doi: 10.1007/s10545-007-0595-x. Epub 2007 Sep 16.

A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease

Affiliations
Multicenter Study

A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease

E H Davies et al. J Inherit Metab Dis. 2007 Oct.

Abstract

Type III Gaucher disease is one of the three recognized subtypes of Gaucher disease, an inherited deficiency of lysosomal glucocerebrosidase. Phenotypically there is a wide spectrum of visceral and neurological manifestations. Enzyme replacement is effective in managing the visceral disease; however, the neurological manifestations remain a more challenging obstacle. There is an unfulfilled need to reliably monitor neurological disease and its response to treatment. A severity scoring tool was developed through neurological domain identification, item generation and tool formation. Domain identification was established based on a retrospective single centre study (n = 15) and a systematic review of publications. Forty-seven patients with neuronopathic Gaucher disease were then assessed using the tool to establish the clinical and statistical reliability of each domain. Judgement quantification of the tool was established through a process of content validity involving five European experts. Content validity is considered to be most effective when undertaken systematically. Concurrent validity and feasibility of the tool was also highlighted. This process allowed a revised and validated version of the tool to be developed.

PubMed Disclaimer

References

    1. Genet Med. 2006 Jan;8(1):8-15 - PubMed
    1. Acta Paediatr. 2006 Mar;95(3):312-7 - PubMed
    1. Eur J Pediatr. 1980 Mar;133(2):107-18 - PubMed
    1. Am J Med Genet. 2002 Nov 1;112(4):347-54 - PubMed
    1. Neuropediatrics. 1995 Aug;26(4):203-7 - PubMed